Business
Press Release May 12 2023
Caplin Point Laboratories Limited has informed the Exchange regarding a press release dated May 12, 2023, titled "Caplin Steriles Limited (Caplin), a Subsidiary Company of Caplin Point Laboratories Limited (BSE: CAPPL (524742), NSE: CAPLIPOINT), has been granted final approval from the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Ketorolac Tromethamine Injection USP.".
About this update from Caplin Point Laboratories Limited
[{"type":"text","content":" Caplin Point Laboratories Limited has informed the Exchange regarding a press release dated May 12, 2023, titled \"Caplin Steriles Limited (Caplin), a Subsidiary Company of Caplin Point Laboratories Limited (BSE: CAPPL (524742), NSE: CAPLIPOINT), has been granted final approval from the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Ketorolac Tromethamine Injection USP.\". View Attachment","length":580,"tagName":"div"}]